z-logo
open-access-imgOpen Access
The Development of Novel Organotin Anti‐Tumor Drugs: Structure and Activity
Author(s) -
Dick de Vos,
Rudolph Willem,
Marcel Gielen,
Kyra E. van Wingerden,
Kees Nooter
Publication year - 1998
Publication title -
metal-based drugs
Language(s) - English
Resource type - Journals
ISSN - 0793-0291
DOI - 10.1155/mbd.1998.179
Subject(s) - in vivo , chemistry , cytotoxicity , cisplatin , solubility , substituent , toxicity , in vitro , pharmacology , doxorubicin , combinatorial chemistry , stereochemistry , organic chemistry , biochemistry , chemotherapy , medicine , biology , microbiology and biotechnology
An overview of the development of anti-tumor organotin derivatives in selected classes of compounds is presented and discussed. High to very high in vitro activity has been found, sometimes equaling that of doxorubicin. Solubility in water is an important issue, dominating the in vivo testing of compounds with promising in vitro properties. The cytotoxicity of the compounds was increased by the presence of a bulky group, an active substituent or one or more polar substituents. Polar substituents may also improve the water solubility. Although organotin derivatives constitute a separate class of compounds, the comparison with cisplatin is inevitable. Among the observed toxicities, neurotoxicity, known from platinum cytostatics, and gastrointestinal toxicity, typical for many oncology drugs, have been detected. Further research to develop novel, useful organotin anti-tumor compounds should be carried out.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom